drugset
drugset / Trial / NCT06558227

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

NCT06558227 ↗

Phase 2 Recruiting 90 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Timeline

Start
2024-10-24
Primary completion
2026-09
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Subject ZG005 Unknown 10 mg/kg Intravenous
Subject ZG005 Unknown 20 mg/kg Intravenous
Background Bevacizumab Monoclonal antibody 15 mg/kg Intravenous

Indications

hepatocellular carcinoma